Literature DB >> 33334202

Epiphyseal cartilage canal architecture and extracellular matrix remodeling in mucopolysaccharidosis VII dogs at the onset of postnatal growth.

Zhirui Jiang1,2, Casey P Johnson3,4, Olli Nykänen5, Mikko Nissi5,6, Yian Khai Lau1,2, Meilun Wu1,2, Margret L Casal7, Lachlan J Smith1,2.   

Abstract

Purpose: Mucopolysaccharidosis (MPS) VII is a genetic, lysosomal storage disease characterized by abnormal accumulation of glycosaminoglycans in cells and tissues. MPS VII patients exhibit multiple failures of endochondral ossification during postnatal growth, including markedly delayed cartilage-to-bone conversion in the vertebrae and long bones. Cartilage canals provide the template for vascularization at the onset of secondary ossification. The objective of this study was to investigate whether abnormal cartilage canal architecture and enzyme-mediated extracellular matrix (ECM) remodeling contribute to delayed cartilage-to-bone conversion in MPS VII.Materials and
Methods: The epiphyseal cartilage canal networks of 9-day-old healthy control and MPS VII-affected dog vertebrae were characterized using high-resolution, contrast-free quantitative susceptibility mapping magnetic resonance imaging. Relative expression levels of matrix metalloproteinases (MMPs) 9, 13 and 14 were examined using immunohistochemistry, while tartrate-resistant acid phosphatase (TRAP) and alkaline phosphatase (ALP) were examined using in situ enzyme staining.
Results: Interestingly, the density, number, connectivity and thickness of cartilage canals was not significantly different between MPS VII and control vertebrae. Immunohistochemistry revealed diminished MMP-9, but normal MMP-13 and 14 expression by epiphyseal cartilage chondrocytes, while ALP and TRAP enzyme expression by chondrocytes and chondroclasts, respectively, were both diminished in MPS VII.Conclusions: Our findings suggest that while the epiphyseal cartilage canal network in MPS VII is normal at the onset of secondary ossification, expression of enzymes required for cartilage resorption and replacement with mineralized ECM, and initiation of angiogenesis, is impaired.

Entities:  

Keywords:  Mucopolysaccharidosis; canine; cartilage canals; endochondral ossification; lysosomal storage disorder; magnetic resonance imaging; quantitative susceptibility mapping

Mesh:

Year:  2021        PMID: 33334202      PMCID: PMC8272733          DOI: 10.1080/03008207.2020.1865939

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  42 in total

1.  User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability.

Authors:  Paul A Yushkevich; Joseph Piven; Heather Cody Hazlett; Rachel Gimpel Smith; Sean Ho; James C Gee; Guido Gerig
Journal:  Neuroimage       Date:  2006-03-20       Impact factor: 6.556

2.  Mechanism of shortened bones in mucopolysaccharidosis VII.

Authors:  Jason A Metcalf; Yanming Zhang; Matthew J Hilton; Fanxin Long; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2009-03-25       Impact factor: 4.797

3.  Susceptibility weighted imaging and quantitative susceptibility mapping of the cerebral vasculature using ferumoxytol.

Authors:  Saifeng Liu; Jean-Christophe Brisset; Jiani Hu; E Mark Haacke; Yulin Ge
Journal:  J Magn Reson Imaging       Date:  2017-07-21       Impact factor: 4.813

4.  VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.

Authors:  Lukas J A C Hawinkels; Kim Zuidwijk; Hein W Verspaget; Eveline S M de Jonge-Muller; Wim van Duijn; Valérie Ferreira; Ruud D Fontijn; Guido David; Daniel W Hommes; Cornelis B H W Lamers; Cornelis F M Sier
Journal:  Eur J Cancer       Date:  2008-08-06       Impact factor: 9.162

Review 5.  Endochondral ossification: how cartilage is converted into bone in the developing skeleton.

Authors:  E J Mackie; Y A Ahmed; L Tatarczuch; K-S Chen; M Mirams
Journal:  Int J Biochem Cell Biol       Date:  2007-06-29       Impact factor: 5.085

6.  Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII.

Authors:  Lachlan J Smith; John T Martin; Spencer E Szczesny; Katherine P Ponder; Mark E Haskins; Dawn M Elliott
Journal:  J Orthop Res       Date:  2010-05       Impact factor: 3.494

7.  Cell cycle progression is disrupted in murine MPS VII growth plate leading to reduced chondrocyte proliferation and transition to hypertrophy.

Authors:  Zhirui Jiang; Ainslie L K Derrick-Roberts; Clare Reichstein; Sharon Byers
Journal:  Bone       Date:  2019-12-18       Impact factor: 4.398

8.  Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis.

Authors:  A R Hayman; S J Jones; A Boyde; D Foster; W H Colledge; M B Carlton; M J Evans; T M Cox
Journal:  Development       Date:  1996-10       Impact factor: 6.868

9.  Improved Visualization of Cartilage Canals Using Quantitative Susceptibility Mapping.

Authors:  Mikko J Nissi; Ferenc Tóth; Luning Wang; Cathy S Carlson; Jutta M Ellermann
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

10.  Development of the cartilage canals and the secondary center of ossification in the distal chondroepiphysis of the prenatal human femur.

Authors:  J K Burkus; T M Ganey; J A Ogden
Journal:  Yale J Biol Med       Date:  1993 May-Jun
View more
  2 in total

Review 1.  Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance.

Authors:  Sandeep Appunni; Muni Rubens; Venkataraghavan Ramamoorthy; Vivek Anand; Madhuram Khandelwal; Alpana Sharma
Journal:  Mol Cell Biochem       Date:  2021-06-28       Impact factor: 3.396

2.  Progression of vertebral bone disease in mucopolysaccharidosis VII dogs from birth to skeletal maturity.

Authors:  Sun H Peck; Yian Khai Lau; Jennifer L Kang; Megan Lin; Toren Arginteanu; Dena R Matalon; Justin R Bendigo; Patricia O'Donnell; Mark E Haskins; Margret L Casal; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2021-06-15       Impact factor: 4.204

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.